In special TME, IFN-activated TANs (such as interferon-induced tetrapeptide repeat (IFIT1)+ TANs in HCC) also exert a pro-tumor or uncertain effect.42 Therefore, the use of IFN+ TANs as therapeutic targets for tumors requires analysis of the specific TME conditions. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.